Physician profile
Dabo Xu
NPI 1649616301
$6,640.37
in general payments reported to CMS, 2019-2025
33 companies · $1,536 in 2025
The $1,536 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $262 · 2022: $917 · 2023: $2,213 · 2024: $1,713 · 2025: $1,536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,461.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,461.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,346.47 | 2022-2025 | Linzess, Creon, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $697.49 | 2022-2025 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $665.11 | 2022-2025 | Vemlidy |
| Pfizer INC. | $602.81 | 2022-2025 | |
| Celgene Corporation | $325.53 | 2022-2024 | Zeposia |
| Qol Medical, LLC | $296.69 | 2023-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $287.29 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $274.69 | 2022-2024 | Ocaliva |
| Janssen Biotech, INC. | $253.09 | 2023-2025 | Stelara, Simponi, Simponi Aria |
| Ardelyx, INC. | $179.48 | 2022-2025 | Ibsrela |
| Nuvasive, INC. | $178.75 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $164.87 | 2022-2024 | Entyvio |
| Regeneron Healthcare Solutions, INC. | $134.81 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $128.36 | 2024-2025 | Rezdiffra, Resmetirom |
| E.R. Squibb & Sons, L.L.C. | $126.87 | 2023 | Zeposia |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $118.01 | 2022-2024 | Dificid, Zinplava |
| Ironwood Pharmaceuticals, INC | $115.92 | 2022-2024 | Linzess |
| Conmed Corporation | $83.33 | 2019 | |
| Eisai INC. | $82.36 | 2024 | |
| Sunovion Pharmaceuticals INC. | $79.73 | 2022 | |
| Celltrion USA INC. | $78.69 | 2024-2025 | Vegzelma |
| Janssen Scientific Affairs, LLC | $75.50 | 2023 | Stelara, Tremfya |
| Intra-Sana Laboratories | $54.75 | 2022-2023 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Braintree Laboratories, INC. | $53.56 | 2022-2023 | Sutab |
| Lilly USA, LLC | $43.75 | 2024-2025 | Omvoh |
| Novo Nordisk INC | $34.82 | 2025 | Wegovy |
| Phathom Pharmaceuticals, INC. | $33.15 | 2024 | Voquezna |
| Amgen INC. | $28.19 | 2023 | Amjevita, Avsola |
| Ipsen Biopharmaceuticals, INC | $22.36 | 2025 | Iqirvo |
| Medtronic, INC. | $20.84 | 2025 | Pillcam |
| Nestle Healthcare Nutrition INC. | $19.22 | 2022 | |
| Horizon Therapeutics Plc | $18.55 | 2022 | |
| Aimmune Therapeutics, INC. | $15.33 | 2025 | Zenpep |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dabo Xu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.